Sotera Health (NASDAQ:SHC) Releases FY 2025 Earnings Guidance

Sotera Health (NASDAQ:SHC) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 0.700-0.760 for the period, compared to the consensus EPS estimate of 0.780. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on SHC. Barclays cut their price objective on shares of Sotera Health from $18.00 to $17.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. Royal Bank of Canada restated an “outperform” rating and issued a $17.00 price target on shares of Sotera Health in a research report on Thursday, November 21st. Citigroup raised their target price on Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Finally, The Goldman Sachs Group started coverage on shares of Sotera Health in a research report on Friday, December 6th. They set a “neutral” rating and a $14.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Sotera Health has an average rating of “Moderate Buy” and a consensus target price of $16.08.

Sotera Health Trading Up 0.7 %

Shares of NASDAQ SHC traded up $0.09 during trading on Friday, reaching $12.37. The stock had a trading volume of 684,580 shares, compared to its average volume of 948,518. Sotera Health has a fifty-two week low of $10.71 and a fifty-two week high of $17.08. The business’s 50-day moving average price is $13.46 and its 200-day moving average price is $14.52. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. The company has a market cap of $3.50 billion, a P/E ratio of 49.54 and a beta of 1.91.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.